Xconomy: Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths

Back Bay’s Managing Partner and CEO, Jonathan Gertler, was quoted in Xconomy article “Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths” by Ben Fidler posted on February 1.

“To me, it’s a rational split,” says Jonathan Gertler, CEO of biotech consulting firm Back Bay Life Science Advisors. Biogen removed the “distraction” of a hemophilia business that the company couldn’t spend the time or resources trying to defend or bolster. “That’s not something that’s core to Biogen,” he says. Add it all up and Bioverativ has some work to do. “If this company rests on its hemophilia revenues,” Gertler says, “it won’t be a success.” 

Read More: Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths